Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01123369 · ClinicalTrials.gov registry record

Spectralis HRA+OCT Imaging of the Retina With Autofluorescence in Sickle Cell Disease

A clinical trial, sponsored by Medical University of South Carolina.

Completed
Registry status
8
Enrollment target

NCT01123369: Completed study, sponsored by Medical University of South Carolina.

NCT01123369 is a clinical trial that has completed, run by Medical University of South Carolina. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01123369 has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
8 participants
Enrollment target

Study Summary

To determine the retinal and choroidal thickness in patients with sickle cell disease compared to age, race matched population without sickle cell disease to allow a better understanding of the clinical manifestations of sickle cell retinopathy. The purpose of this research study is to evaluate the relationship between sickle cell disease and the eye. The research study is recruiting African American population with or without Sickle Cell Disease. The investigator in charge of this study is Dr E. Bowie. Approximately 60 subjects of both sexes will be enrolled at the Medical University of South Carolina.

Primary Outcome

The use of Spectralis HRA+OCT gives us visualization of the individual layers of the retina to determine if there are underlying changes not seen clinically in the gross ophthalmic posterior segment exam. This knowledge will aid the care of African-Americans with sickle cell disease to enable greater understanding of the ocular disease progression leading to earlier eye screenings, possible novel treatments and ultimately visual loss prevention

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2010-02
Est. Completion 2010-07

What the finished NCT01123369 record still lists

NCT01123369 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT01123369 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01123369 about?

NCT01123369 is a clinical study titled "Spectralis HRA+OCT Imaging of the Retina With Autofluorescence in Sickle Cell Disease". To determine the retinal and choroidal thickness in patients with sickle cell disease compared to age, race matched population without sickle cell disease to allow a better understanding of the clinical manifestations of sickle cell retinopathy. The purpose of this research study is to evaluate the ...

What is the current status of trial NCT01123369?

This trial is currently completed. The enrollment target is 8 participants. The study started on 2010-02. Estimated completion is 2010-07.

Who is sponsoring clinical trial NCT01123369?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01123369, the US trial registry maintained by the National Library of Medicine. NCT01123369 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.